ClinicalTrials.gg
CompletedNCT03640754Updated Nov 28, 2023Results posted

A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women

A Phase 1 interventional study of G-CSF and Placebo/Saline in Postmenopausal Symptoms, sponsored by MenoGeniX, Inc.. Completed at 2 sites in United States. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by MenoGeniX, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.

Enrollment
103rd of 180
61 · median 84
Started
2018
with 7 others
Phase 1
13 of 193
none open now
Registered
142nd of 193
by date

Among the 193 studies in Hot Flashes with a site in United States, this one is the 103rd largest by enrollment of the 180 interventional ones that give a count, is one of 8 that started in 2018, is one of 13 in phase 1, and was the 142nd registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Hot Flashes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgically induced menopause. G-CSF will be administered three times at 28 day intervals to postmenopausal women, ages 40 to 65, suffering at least 49 moderate to severe hot flashes per week.

Read the detailed description

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled study. Eligible subjects will be stratified by natural or surgical menopause and randomized (1:1) to receive 3 single injections, 28-days apart, of either G-CSF or placebo.

This study will consist of a 14-21 day screening period. Subjects enrolled will be given three single 1.0 mL subcutaneous (SC) injections (repeated 28-days apart), in the outer area of either upper arm, of either G-CSF or placebo (sterile physiological saline) at Baseline, Day 28 and Day 56. Subjects will be followed for 12 weeks and will complete hot flash diary entries every day for the duration of treatment. Safety will be assessed by adverse events, clinical laboratory tests (clinical chemistry and complete blood count with differential) and vital signs. A follow-up phone call will occur 60 days after the last dose of study drug.

Eligibility will be assessed via physical examination, clinical laboratory testing, vital signs.

Subjects will receive a diary in which to record daily hot flashes symptoms during the duration of the screening period. Subjects must have at least 14 days of hot flash recordings to participate in the study. The diary will be reviewed by study site staff on Baseline (Day 0) to confirm study eligibility.

During the treatment period, subjects will return to the study site at Days 1, 21, 28, 29, 49, 56, 57, and 84 for assessments.

The follow-up phone call will occur approximately 60 days following the last dose of study drug.

03

Conditions studied

  • Postmenopausal Symptoms

Browse trials for

Keywords

  • Hot Flashes
  • Vasomotor Symptoms
  • Menopause
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, aged 49 to 65 for natural or aged 40 to 65 for surgical postmenopausal
  • (BMI) 18 to 35
  • At least 7 moderate to severe hot flashes per day on average (or at least 49 moderate to severe hot flashes per week)
  • Naturally postmenopausal or surgically postmenopausal women:
  • Naturally postmenopausal is defined as having no menstrual periods for at least 12 months prior to study entry; with a biochemical criteria of menopause (FSH >40 IU/L)
  • Surgically postmenopausal is defined as at least 3 months after documented bilateral salpingo oophorectomy
  • Normal pelvic exam and pap smear within 2 years
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Radiation or chemotherapy-induced (including gonadotropin-releasing hormone (GnRH) agonist) menopause
  • Prior chemotherapy or radiation therapy for cancer
  • Prior diagnosis of hematologic
  • Type 1 diabetics or Type 2 diabetics with > 7.0%
  • Use of hormone replacement therapy or oral within the past three months
  • Use of alternative or complementary medicines or herbs for menopausal symptoms within 30 days (refer to Appendix 2)
  • Use of any selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) within 30 days
  • Use of selective estrogen receptor modulators within 30 days
  • Use of gabapentin within 30 days
  • Use of clonidine within 30 days
  • Use of megestrol acetate (Megace) within 30 days
  • Use of, prescription within 30 days (nasal or other inhaled corticosteroids and over-the-counter (OTC) hydrocortisone ointment or cream excepted)
  • Current use of lithium therapy (related to possible risk of G-CSF)
  • History (in the past year) or presence of drug or alcohol use which, in the opinion of the Investigator, might compromise the study or confound the study results
  • History of use of any anti-inflammatory biologics
  • History of or current splenomegaly (related to possible risk of G-CSF)
  • History of sickle cell disease (related to possible risk of G-CSF)
  • High risk for medical complications that might affect the subject's ability to complete the trial without a serious co-morbid event, based on medical history, physical examination and laboratory screening evaluation in the opinion of the Investigator
  • Presence of an acute or chronic condition (such as a hematological, rheumatologic auto-immune disease, chronic inflammatory disorder or osteoporosis) based on history, clinical, or laboratory evaluation, which, in the opinion of the Investigator, might compromise the study, confound the study results or place the subject at risk
  • Follicle stimulating hormone (FSH) \< 40 IU/L or below the reference range for menopause for the local laboratory used for screening
  • Thyroid stimulating hormone (TSH) outside normal limits at study entry
  • (ANC) ≤ 1.0 x 109/L
  • Total white blood cell count (WBC) ≤ 3.0 x 109/L
  • count (PLT) ≤ 150 x 109/L
  • count (HGB) consistent with anemia
  • Positive urine pregnancy test at Baseline visit
  • Allergy or to E coli-derived proteins' G-CSF' or any component of the product
  • Mentally or legally incapacitated such that cannot be obtained
  • Inability or unwillingness to complete daily hot flash diary and study questionnaires appropriately
  • Participation in another trial within the past 30 days
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Active comparator
    Experimental: G-CSF

    Intervention: G-CSF given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Filgrastim

    Biological: G-CSF

  • Placebo comparator
    Comparator: Placebo/Saline

    Intervention: Placebo/saline given by subcutaneous injection repeated 3 times (Days 0, 28, 56) Other name: Saline

    Other: Placebo/Saline

Interventions

  • BiologicalG-CSF

    G-CSF injected subcutaneously 3 times (Days 0, 28, 56)

    Also known as: Filgrastim

  • OtherPlacebo/Saline

    Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is any untoward medical occurrence, including the exacerbation of a pre-existing condition, in a subject or clinical investigation subject administered a pharmaceutical product. This does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution. This includes any experience that results in death; is acutely life-threatening; requires inpatient hospitalization or prolongs the existing hospitalization; results in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; is a congenital anomaly/birth defect; or requires medical or surgical intervention to prevent one of the outcomes listed above.

    Time frame: From first dose date up to 30 days after last dose (up to 16 weeks)

  2. Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 0

    Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 0. Blood samples were collected 24 hours after adminstration of G-CSF on day 0.

    Time frame: Baseline and day 1

  3. Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 28

    Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 28. Blood samples were collected 24 hours after adminstration of G-CSF on day 28.

    Time frame: Baseline and day 29

  4. Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 56.

    Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 56. Blood samples were collected 24 hours after adminstration of G-CSF on day 56.

    Time frame: Baseline and day 57

  5. Change From Baseline in White Blood Cell Counts on Day 84 (28 Days After Last Administration of G-CSF or Palcebo)

    Change from baseline in white blood cell counts on day 84. Blood samples were collected 24 hours after adminstration of G-CSF on day 84.

    Time frame: Baseline and day 84

  6. Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 4

    The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

    Time frame: Baseline and week 4

  7. Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 12

    The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

    Time frame: Baseline and week 12

  8. Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 4

    CDS (Composite Daily Hot Flash Severity) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

    Time frame: Baseline and week 4

  9. Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 12

    CDS (Composite Daily Hot Flash Severity) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

    Time frame: Baseline and week 12

  10. Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 4

    HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

    Time frame: Baseline and week 4

  11. Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 12

    HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

    Time frame: Baseline and week 12

Secondary outcomes

  1. Number of Subjects Achieving >50% Reduction in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes up to Week 12

    The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

    Time frame: Weeks 1-12

  2. Number of Subjects Acheiving >50% Reduction in the Mean Composite Daily Hot Flash Severity (CDS) up to Week 12

    CDS was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

    Time frame: Weeks 1-12

  3. Number of Subjects Acheiving >0.30 Reduction in the Mean Daily Hot Flash Severity Score (HFSS) up to Week 12

    HFSS was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. HFSS = ((number of daily mild hot flashes x1) + (number of daily moderate hot flashes x2) + (number of severe hot flashes x3))/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe (S) hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received. Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.

    Time frame: Weeks 1-12

  4. Percent Change in M+S at 12 Weeks in Demographic Subgroups

    The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

    Time frame: Baseline and Week 12

  5. Net Change in HFSS at 12 Weeks in Demographic Subgroups

    HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. HFSS = ((number of daily mild hot flashes x1) + (number of daily moderate hot flashes x2) + (number of severe hot flashes x3))/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe (S) hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received

    Time frame: Baseline and Week 12

  6. Net Change in MENQOL VMS Score

    Menopause-specific Quality of Life (MENQOL) Questionnaire. The MENQOL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of one of four domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29). MENQOL VMS refers to the answers to items 1-3 where 6 = most bothersome and 0 = least bothersome). (Maximum bothersomeness = 18; No bothersomeness = 0)

    Time frame: Baseline and week 12

  7. Net Change in HFRDIS Score

    The Hot Flash Related Daily Interference Scale (HFRDIS) measures (as a score of 0 to 10) the effect of hot flashes on overall quality of life and on nine specific activities: work, social activities, leisure activities, sleep, mood, concentration, relations with others, sexuality, and enjoyment of life. The 10 answers are added up to get a total score. HFRDIS Score (Maximum Bothersomness = 100; No Bothersomeness = 0). The higher the score, the more bothersome the symptoms.

    Time frame: Baseline and week 12

  8. Net Change in ISI Score at 12 Weeks

    The Insomnia Severity Index has seven questions. For each question, most bothersome = 4; not bothersome = 0. The seven answers are added up to get a total score. Total score categories: 0-7 = No clinically significant insomnia; 8-14 = Subthreshold insomnia; 15-21 = Clinical insomnia (moderate severity); 22-28 = Clinical insomnia (severe)

    Time frame: Baseline and week 12

  9. Net Change in FSS Score at 12 Weeks

    Fatigue Severity Scale (FSS) of Sleep Disorders. The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue. The FSS is a short questionnaire (10 questions) that requires the subject to rate level of fatigue. The FSS questionnaire contains nine statements that rate the severity of fatigue symptoms. Each statement is read and the corresponding number from 1 to 7 is circled. A low value (e.g., 1) indicates strong disagreement with the statement, whereas a high value (e.g., 7) indicates strong agreement. (Maximum bother = 70; No bother = 0)

    Time frame: Baseline and week 12

07

Results

Posted Nov 28, 2023

Participant flow

Postmenopausal women participants 40 to 65 years of age who had moderate to severe vasomotor symptoms (VMS) and seeking treatment or relief for hot flashes associated with menopause, confirmed as menopausal, had to have 7 to 8 moderate to severe hot flashes per day within the 7 days prior to randomization and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study. A total of 61 subjects were randomized to receive G-CSF or saline in this trial.

Participant flow — Overall Study
MilestoneExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)
Started3130
Completed3029
Not completed11
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up01

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is any untoward medical occurrence, including the exacerbation of a pre-existing condition, in a subject or clinical investigation subject administered a pharmaceutical product. This does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution. This includes any experience that results in death; is acutely life-threatening; requires inpatient hospitalization or prolongs the existing hospitalization; results in persistent or significant incapacity or substantial disruption of ability to conduct normal life functions; is a congenital anomaly/birth defect; or requires medical or surgical intervention to prevent one of the outcomes listed above.

Time frame:
From first dose date up to 30 days after last dose (up to 16 weeks)
Reported as:
Number · Participants
Number of Participants With Adverse Events
ParticipantsExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Treatment Emergent Adverse Events (TEAE)24201210
Drug-related TEAE12353
Serious TEAE0000
Drug-related serious TEAE0000
TEAE leading to death0000
TEAE leading to withdrawal of treatment0000
PrimaryChange From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 0

Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 0. Blood samples were collected 24 hours after adminstration of G-CSF on day 0.

Time frame:
Baseline and day 1
Reported as:
Mean · Number of white blood cells per mL
Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 0
Number of white blood cells per mLExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 017493 ± 822103 ± 14417394 ± 1095144 ± 210
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · t-test, 1 sided · p = <0.001
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · t-test, 1 sided · p = <0.001
PrimaryChange From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 28

Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 28. Blood samples were collected 24 hours after adminstration of G-CSF on day 28.

Time frame:
Baseline and day 29
Reported as:
Mean · Number of white blood cells per mL
Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 28
Number of white blood cells per mLExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 2818273 ± 98813 ± 18218378 ± 114767 ± 230
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · t-test, 1 sided · p = <0.001
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · t-test, 1 sided · p = <0.001
PrimaryChange From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 56.

Change from baseline in white blood cell counts 24 hours after administration of G-CSF or placebo on day 56. Blood samples were collected 24 hours after adminstration of G-CSF on day 56.

Time frame:
Baseline and day 57
Reported as:
Mean · Number of white blood cells per mL
Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 56.
Number of white blood cells per mLExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Change From Baseline in White Blood Cell Counts 24 Hours After Administration of G-CSF or Placebo on Day 56.16403 ± 144537 ± 20815128 ± 2112150 ± 340
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · t-test, 1 sided · p = <0.001
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · t-test, 1 sided · p = <0.001
PrimaryChange From Baseline in White Blood Cell Counts on Day 84 (28 Days After Last Administration of G-CSF or Palcebo)

Change from baseline in white blood cell counts on day 84. Blood samples were collected 24 hours after adminstration of G-CSF on day 84.

Time frame:
Baseline and day 84
Reported as:
Mean · Number of white blood cells per mL
Change From Baseline in White Blood Cell Counts on Day 84 (28 Days After Last Administration of G-CSF or Palcebo)
Number of white blood cells per mLExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Change From Baseline in White Blood Cell Counts on Day 84 (28 Days After Last Administration of G-CSF or Palcebo)-107 ± 311-420 ± 311-611 ± 297-256 ± 265
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · t-test, 1 sided · p = 0.199
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · t-test, 1 sided · p = 0.189
PrimaryChange From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 4

The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

Time frame:
Baseline and week 4
Reported as:
Least squares mean · Number of hot flashes per day
Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 4
Number of hot flashes per dayExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 4-3.9 (-5.7 to -2.2)-4.0 (-5.7 to -2.3)-4.1 (-6.4 to -1.8)-4.0 (-6.2 to -1.7)
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · Mixed Models Analysis · p = 0.398
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · Mixed Models Analysis · p = 0.391
PrimaryChange From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 12

The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · Number of hot flashes per day
Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 12
Number of hot flashes per dayExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Change From Baseline in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes at Week 12-6.4 (-8.2 to -4.7)-6.0 (-7.7 to -4.3)-7.5 (-9.9 to -4.3)-4.5 (-6.8 to -2.2)
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · Mixed Models Analysis · p = 0.232
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · Mixed Models Analysis · p = 0.085
PrimaryChange From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 4

CDS (Composite Daily Hot Flash Severity) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

Time frame:
Baseline and week 4
Reported as:
Least squares mean · Number of hot flashes per day
Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 4
Number of hot flashes per dayExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 4-10 (-15 to -5.5)-11 (-15 to -6.2)-11 (-17 to -4.3)-10 (-17 to -4.3)
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · Mixed Models Analysis · p = 0.501
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · Mixed Models Analysis · p = 0.370
PrimaryChange From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 12

CDS (Composite Daily Hot Flash Severity) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · Number of hot flashes per day
Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 12
Number of hot flashes per dayExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Change From Baseline in the Mean Composite Daily Severity of Hot Flashes (CDS) at Week 12-17 (-22 to -12)-16 (-21 to -12)-19 (-25 to -13)-12 (-18 to -5.4)
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · Mixed Models Analysis · p = 0.333
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · Mixed Models Analysis · p = 0.014
PrimaryChange From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 4

HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

Time frame:
Baseline and week 4
Reported as:
Least squares mean · Hot flash severity score
Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 4
Hot flash severity scoreExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 4-0.09 (-0.31 to 0.13)-0.08 (-0.31 to 0.13)-0.11 (-0.47 to 0.24)-0.07 (-0.42 to 0.28)
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · Mixed Models Analysis · p = 0.124
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · Mixed Models Analysis · p = 0.175
PrimaryChange From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 12

HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

Time frame:
Baseline and week 12
Reported as:
Least squares mean · Hot flash severity score
Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 12
Hot flash severity scoreExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Change From Baseline in the Mean Daily Severity of Hot Flashes (HFSS) at Week 12-0.31 (-0.53 to -0.09)-0.13 (-0.34 to 0.09)-0.43 (-0.79 to -0.08)-0.19 (-0.55 to 0.17)
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · Mixed Models Analysis · p = 0.032
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · Mixed Models Analysis · p = 0.077
SecondaryNumber of Subjects Achieving >50% Reduction in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes up to Week 12

The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

Time frame:
Weeks 1-12
Reported as:
Number · Number of subjects
Number of Subjects Achieving >50% Reduction in the Mean Frequency of Moderate and Severe (M+S) Hot Flashes up to Week 12
Number of subjectsExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Week 15423
Week 28753
Week 37954
Week 48854
Week 5159103
Week 61512105
Week 71512105
Week 8121375
Week 9151094
Week 10141295
Week 11151396
Week 12151496
SecondaryNumber of Subjects Acheiving >50% Reduction in the Mean Composite Daily Hot Flash Severity (CDS) up to Week 12

CDS was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

Time frame:
Weeks 1-12
Reported as:
Number · Number of subjects
Number of Subjects Acheiving >50% Reduction in the Mean Composite Daily Hot Flash Severity (CDS) up to Week 12
Number of subjectsExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Week 15423
Week 28753
Week 37854
Week 47744
Week 5159103
Week 61413106
Week 71511105
Week 8121174
Week 9141185
Week 10131285
Week 11151396
Week 12151395
SecondaryNumber of Subjects Acheiving >0.30 Reduction in the Mean Daily Hot Flash Severity Score (HFSS) up to Week 12

HFSS was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. HFSS = ((number of daily mild hot flashes x1) + (number of daily moderate hot flashes x2) + (number of severe hot flashes x3))/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe (S) hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received. Severity was zero for participants that had no mild or moderate or severe VMS. Higher scores indicates greater severity.

Time frame:
Weeks 1-12
Reported as:
Number · Number of subjects
Number of Subjects Acheiving >0.30 Reduction in the Mean Daily Hot Flash Severity Score (HFSS) up to Week 12
Number of subjectsExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Week 14423
Week 24532
Week 37644
Week 45634
Week 56634
Week 68563
Week 77654
Week 87654
Week 99573
Week 108462
Week 119563
Week 127663
SecondaryPercent Change in M+S at 12 Weeks in Demographic Subgroups

The frequency of moderate to severe hot flashes was the number of moderate to severe hot flashes per 24 hours. A daily frequency per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received.

Time frame:
Baseline and Week 12
Reported as:
Mean · Percent change in hot flashes
Percent Change in M+S at 12 Weeks in Demographic Subgroups
Percent change in hot flashesExperimental: G-CSF (White, Not Hispanic Subjects)Comparator: Placebo (White, Not Hispanic Subjects)Experimental: G-CSF (Hispanic Subjects)Comparator: Placebo (Hispanic Subjects)Experimental: G-CSF (Black Subjects)Comparator: Placebo (Black Subjects)
Percent Change in M+S at 12 Weeks in Demographic Subgroups-51 ± 8-33 ± 8-32 ± 18-62 ± 15-46 ± 18-55 ± 14
Statistical analysis
  • Experimental: G-CSF (White, Not Hispanic Subjects) vs Comparator: Placebo (White, Not Hispanic Subjects) · t-test, 1 sided · p = 0.047
  • Experimental: G-CSF (Hispanic Subjects) vs Comparator: Placebo (Hispanic Subjects) · t-test, 1 sided · p = 0.139
  • Experimental: G-CSF (Black Subjects) vs Comparator: Placebo (Black Subjects) · t-test, 1 sided · p = 0.395
SecondaryNet Change in HFSS at 12 Weeks in Demographic Subgroups

HFSS (Daily Hot Flash Severity Score) was calculated as follows: \[(number of mild hot flashes per day x 1) + (number of moderate hot flashes per day x 2) + (number of severe hot flashes per day x 3)\]. HFSS = ((number of daily mild hot flashes x1) + (number of daily moderate hot flashes x2) + (number of severe hot flashes x3))/daily total hot flashes), where total hot flashes (THF) = number of daily mild, moderate, and severe (S) hot flashes. A daily severity score per week was derived by taking the mean of the data over 7 days. All subjects who were randomized and received at least one dose of study drug are included in this subset. Subjects are analysed according to the randomized treatment group regardless of treatment received

Time frame:
Baseline and Week 12
Reported as:
Mean · Hot flash severity score
Net Change in HFSS at 12 Weeks in Demographic Subgroups
Hot flash severity scoreExperimental: G-CSF (White Subjects)Comparator: Placebo (White Subjects)Experimental: G-CSF (Hispanic Subjects)Comparator: Placebo (Hispanic Subjects)Experimental: G-CSF (Black Subjects)Comparator: Placebo (Black Subjects)
Net Change in HFSS at 12 Weeks in Demographic Subgroups-0.29 ± 0.16-0.09 ± 0.110.13 ± 0.14-0.13 ± 0.2-0.14 ± 0.10.13 ± 0.21
Statistical analysis
  • Experimental: G-CSF (White Subjects) vs Comparator: Placebo (White Subjects) · t-test, 1 sided · p = 0.147
  • Experimental: G-CSF (Hispanic Subjects) vs Comparator: Placebo (Hispanic Subjects) · t-test, 1 sided · p = 0.160
  • Experimental: G-CSF (Black Subjects) vs Comparator: Placebo (Black Subjects) · t-test, 1 sided · p = 0.152
SecondaryNet Change in MENQOL VMS Score

Menopause-specific Quality of Life (MENQOL) Questionnaire. The MENQOL is self-administered and consists of a total of 29 items in a Likert-scale format. Each item assesses the impact of one of four domains of menopausal symptoms, as experienced over the last month: vasomotor (items 1-3), psychosocial (items 4-10), physical (items 11-26), and sexual (items 27-29). MENQOL VMS refers to the answers to items 1-3 where 6 = most bothersome and 0 = least bothersome). (Maximum bothersomeness = 18; No bothersomeness = 0)

Time frame:
Baseline and week 12
Reported as:
Mean · Score on a scale
Net Change in MENQOL VMS Score
Score on a scaleExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Net Change in MENQOL VMS Score-5.7 ± 1.0-4.8 ± 1.2-6.0 ± 1.2-3.6 ± 1.5
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · t-test, 1 sided · p = 0.286
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · t-test, 1 sided · p = 0.107
SecondaryNet Change in HFRDIS Score

The Hot Flash Related Daily Interference Scale (HFRDIS) measures (as a score of 0 to 10) the effect of hot flashes on overall quality of life and on nine specific activities: work, social activities, leisure activities, sleep, mood, concentration, relations with others, sexuality, and enjoyment of life. The 10 answers are added up to get a total score. HFRDIS Score (Maximum Bothersomness = 100; No Bothersomeness = 0). The higher the score, the more bothersome the symptoms.

Time frame:
Baseline and week 12
Reported as:
Mean · score on a scale
Net Change in HFRDIS Score
score on a scaleExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Net Change in HFRDIS Score-22.5 ± 6.1-26.7 ± 4.5-21.2 ± 7.7-25.1 ± 5.0
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · t-test, 1 sided · p = 0.289
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · t-test, 1 sided · p = 0.338
SecondaryNet Change in ISI Score at 12 Weeks

The Insomnia Severity Index has seven questions. For each question, most bothersome = 4; not bothersome = 0. The seven answers are added up to get a total score. Total score categories: 0-7 = No clinically significant insomnia; 8-14 = Subthreshold insomnia; 15-21 = Clinical insomnia (moderate severity); 22-28 = Clinical insomnia (severe)

Time frame:
Baseline and week 12
Reported as:
Mean · score on a scale
Net Change in ISI Score at 12 Weeks
score on a scaleExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Net Change in ISI Score at 12 Weeks-5.5 ± 1.5-6.0 ± 1.1-4.6 ± 2.0-3.8 ± 1.4
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · t-test, 1 sided · p = 0.393
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · t-test, 1 sided · p = 0.365
SecondaryNet Change in FSS Score at 12 Weeks

Fatigue Severity Scale (FSS) of Sleep Disorders. The Fatigue Severity Scale (FSS) is a method of evaluating the impact of fatigue. The FSS is a short questionnaire (10 questions) that requires the subject to rate level of fatigue. The FSS questionnaire contains nine statements that rate the severity of fatigue symptoms. Each statement is read and the corresponding number from 1 to 7 is circled. A low value (e.g., 1) indicates strong disagreement with the statement, whereas a high value (e.g., 7) indicates strong agreement. (Maximum bother = 70; No bother = 0)

Time frame:
Baseline and week 12
Reported as:
Mean · score on a scale
Net Change in FSS Score at 12 Weeks
score on a scaleExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
Net Change in FSS Score at 12 Weeks-5.3 ± 3.0-6.2 ± 2.2-6.9 ± 3.7-7.0 ± 2.8
Statistical analysis
  • Experimental: G-CSF (All Subjects) vs Comparator: Placebo/Saline (All Subjects) · t-test, 1 sided · p = 0.406
  • Experimental: G-CSF (White, NH Subgroup) vs Comparator: Placebo/Saline (White, NH Subgroup) · t-test, 1 sided · p = 0.494

Adverse events

Collected over From first dose date up to 30 days after last dose (up to 16 weeks). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: G-CSF (All Subjects)0/30 (0%)0/30 (0%)24/30 (80%)
Comparator: Placebo/Saline (All Subjects)0/30 (0%)0/30 (0%)20/30 (66.7%)
Experimental: G-CSF (White, NH Subgroup)0/18 (0%)0/18 (0%)12/18 (66.7%)
Comparator: Placebo/Saline (White, NH Subgroup)0/18 (0%)0/18 (0%)10/18 (55.6%)
Most frequent other events
Most frequent other events
EventExperimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Experimental: G-CSF (White, NH Subgroup)Comparator: Placebo/Saline (White, NH Subgroup)
GeneralGeneral disorders10/3014/306/187/18
Musculo/Skeletal (not incl. bone pain)Musculoskeletal and connective tissue disorders9/306/305/182/18
Cold/SinusInfections and infestations8/307/304/185/18
HeadacheGeneral disorders6/301/304/181/18
FatigueGeneral disorders6/303/302/182/18
Nausea/GI DisordersGastrointestinal disorders4/304/303/180/18
Bone PainMusculoskeletal and connective tissue disorders2/300/302/180/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Experimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Total
Mean55.4 ± 4.3955.6 ± 4.5855.5 ± 4.45
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Total
Female313061
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Total
Hispanic or Latino6612
Not Hispanic or Latino252449
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Total
American Indian or Alaska Native101
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American6713
White222345
More than one race000
Unknown or Not Reported202
Daily Moderate + Severe Hot Flashes (M+S)
Daily Moderate + Severe Hot Flashes (M+S)(Number of hot flashes per day)Experimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Total
Mean12.5 ± 5.1412.3 ± 4.7312.4 ± 4.9
Composite Daily Hot Flash Severity (CDS)
Composite Daily Hot Flash Severity (CDS)(Number of hot flashes per day)Experimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Total
Mean33.7 ± 12.7233.7 ± 14.4433.7 ± 13.49
Hot Flash Severity Score (HFSS)
Hot Flash Severity Score (HFSS)(Score on a scale)Experimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Total
Mean2.3 ± 0.322.4 ± 0.352.3 ± 0.34
White Blood Cell Counts (WBC)
White Blood Cell Counts (WBC)(White Blood Cells per mL)Experimental: G-CSF (All Subjects)Comparator: Placebo/Saline (All Subjects)Total
Mean6007 ± 19236142 ± 12966088 ± 1633

4 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Site 2
    Aurora, Colorado 80045, United States
  • Site 1
    Denver, Colorado 80209, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Jan 2022, 41 months.

Results were first posted in Nov 2023, 1 year 10 months after primary completion.

Of 10 phase 1 interventional studies under Hot Flashes, half reached primary completion within 3 months of starting (the median); a quarter within 1 and three quarters within 9. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2018
First posted
Aug 21, 2018
StartActual
Aug 6, 2018
Primary completionActual
Jan 21, 2022
CompletionActual
Feb 22, 2022
Results first posted
Nov 28, 2023
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03640754
Lead sponsor
MenoGeniX, Inc.
Responsible party
Sponsor
First posted
Aug 21, 2018
Start date
Aug 6, 2018
Primary completion
Jan 21, 2022
Completion
Feb 22, 2022
Results posted
Nov 28, 2023
Last update
Nov 28, 2023

Study contacts

Richard C Duke, PhD
study chair · MenoGeniX, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Granulocyte Colony-Stimulating Factor

Start the discussion